Nonalcoholic fatty liver disease (NAFLD). Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: In intervention group, two Gerilact tablets 500 mg will be administered daily for 60 days. Intervention 2: In control group, two placebo tablets will be given daily for 60 days.
Treatment - Drugs
Placebo
In intervention group, two Gerilact tablets 500 mg will be administered daily for 60 days
In control group, two placebo tablets will be given daily for 60 days
Sponsors
Vice chancellor for research, Ardabil University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with newly diagnosed fatty liver grade II and III; with no treatment for NAFLD; BMI 25-40 kg/m2; over 18 years old. Exclusion criteria: any gastrointestinal disease; diabetes mellitus; cardiac or kidney failure; thyroid disease; rheumatoid arthritis; chronic liver disease beside NAFLD; cancer; antibiotic therapy two weeks prior or during study; vitamin, antioxidant, fiber and omega3 complement use 3 weeks prior or during study; pregnancy or breast feeding, OCP use; liver transplantation; alcohol use.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid profile. Timepoint: Before and at the end of intervention. Method of measurement: with laboratory examination.;Liver function tests. Timepoint: Before and at the end of intervention. Method of measurement: with laboratory examination.;Fatty liver grade. Timepoint: Before and at the end of intervention. Method of measurement: With sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Zahra Sadeghi
Ardabil University of Medical Sceinces
Outcome results
None listed